NEW YORK (GenomeWeb) – Enzo Biochem today reported flat year-over-year revenues for its fiscal third quarter. 

For the three months ended April 30, the firm recorded total revenues of $24 million, the same as a year ago. Enzo Clinical Labs' revenues were up 8 percent to $15.7 million from $14.5 million, but Life Sciences revenues, which comprise Enzo's product revenues, slid 9 percent to $7.9 million from $8.7 million due to the effects of currency exchange and the timing of customer reordering patterns, Enzo said. Royalty and license fee income dropped to $423,000 from $729,000. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.